Trial Profile
An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 16 Jan 2020 Results published in the Investigational New Drugs
- 01 Sep 2018 Results published in the Cancer Science
- 12 Jul 2018 Status changed from active, no longer recruiting to completed.